Healthcare has become the second-best performer in the S&P 500 (SP500) this month, prompting market observers to foresee a brighter 2025 for a sector that has struggled to outperform the broader index ...

Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.

Trump’s White House juggled a devastating American Airline flight-Black Hawk helicopter crash, a Chinese AI threat and looming tariffs just this week alone, making for a busy start to his four-year ...

FAA imposes helicopter restrictions near Reagan National Airport; U.S. readies for tariffs on imports from Mexico, Canada and ...

Liquidia Corporation's litigation battle and upcoming commercial launch of its primary candidate, YUTREPIA, take spotlight.

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Stocks traded mostly lower on Friday after President Donald Trump followed through on his pledge to enact tariffs on Mexico ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Shares of ResMed (NYSE:RMD) fell 6% today, despite the company reporting second-quarter earnings that surpassed analyst ...

Zimmer Biomet Holdings, Inc. ZBH is scheduled to report fourth-quarter 2024 results on Feb. 6, before market open. See the ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

The stock market showed resilience after Monday's DeepSeek-spurred sell-off in AI hardware stocks. Apple, Tesla, Microsoft led big earnings.